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ABSTRACT 
Bluetongue is an infectious arthropod-bome viral disease affecting sheep, domestic and 
wild ruminants caused by Bluetongue Virus (BTV) and transmitted by few species of 
Culicoides (Diptera: Ceratopogonidae). Since 1998, outbreaks of BT involving 
6 distinct serotypes have occurred in the Mediterranean basin. The only BTV vaccines 
currently available are serotype specific. Objectives: The development of recombinants 
capripoxvirus for protective immunization of ruminants against bluetongue virus (BTV) 
infection is described here. Metbodology: Sheep (n= l 1) and goats (n=4) were 
immunized with bluetongue recombinant capripoxvirus (BTV-Cpox) expressing 
individually four different genes encoding two capsid proteins (VP2 and VP7) and two 
non-structural proteins (NSI , NS3) of Bluetongue virus serotype 2 (BTV-2). Results: 
Seroconversion was observed against NS3 , VP7 and VP2 in botb groups of animais. A 
specific BTV antigens lymphoproliferation observed in goats corroborates with a partial 
protection in sheep challenged with a virulent strain of BTV-2. 
INTRODUCTION 
Since 1998, outbreaks of BT involving 6 distinct serotypes have occurred 
in the Mediterranean basin . The only BTV vaccines currently available 
are serotype specific Previous studies involving coexpression of VP2 and 
VP5 as virus like particles (VLPs) or in combination with core proteins 
confirmed the viability of a subunit BTV vaccination strategy. However, 
these vaccines have not yet been adopted for field use. A recent study 
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using recombinant canarypox virus coexpressing genes encoding the VP2 
and VP5 induced high level of protection in sheep but still remains 
serotype specific (Boone et al. , 2007). ln contrast, expression of VP7 by 
a recombinant capripoxvirus provided partial protection of sheep against 
a virulent heterotypic BT virus challenge (Wade-Evans, 1996). In this 
study, recombinant capripoxviruses (BTV-Cpox), expressing VP2 or the 
conserved VP7, NSl and NS3 proteins derived from BTV serotype 
2 were developed in order to induce a beterotypic protection. These 
BTV-Cpox recombinants were administrated to goats and sheep and 
immune responses were evaluated in botb species. Sheep were also 
challenged with a virulent strain of BT serotype 2. 
CLONING OF BTV GENES AND GENERATION OF 
CAPRIPOXVIRUSES 
The four distinct full-length BTV genes NSl , NS3, VP7 and VP2 were 
cloned from a Corsican strain of BTV-2 into pKSCATpSGPT, a shuttle 
plasmid. All BTV genes were placed under the contrai of the early/late 
synthetic promote (PS) from vaccinia virus. The Escherichia coli xanthine-
guanine phospboribosyltransferase gene (Ecogpt), also under control of the 
PS promoter but in the opposite orientation, was used as a dominant 
selectable marker to isolate the recombinants (Boyle et al. , 1988; Falkner 
et al. , 1988). The insertions site in the capripoxvirus genome was the viral 
thymidine kinase (TK) gene as the site for insertion (Wallace, 2005). Final 
constructions were used to generate recombinant capripoxviruses by 
transfection of OA3Ts as described in Romero et al. , 1993. 
IMMUNIZATION OF GOATS AND SHEEP 
Two groups of four Saanen goats and twenty-one Pré-Alpes sheep, 
purchased from a French region free of BTV infection were housed 
respectively in an insect proof stabling facility or a level 3 stabling 
facility. Animais were individually inoculated subcutaneously with either 
a suspension of 2.106 TCID50 of an irrelevant recombinant capripox-
HPPR vaccine expressing the haemagglutinin of the peste des petits 
ruminants virus ( control group) or with 2.106 TCID50 of each BTV-Cpox 
recombinant vaccine (BT-Cpox group). Three weeks after inoculation, all 
animais were challenged subcutaneously with either 104 TCID50 of the 
BTV-2 attenuated vaccine strain for goats or virulent BTV-2 strain for 
sheep. Whole blood (EDTA and heparinised) was collected respectively 
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for RNA extraction and PBMCs isolation. Serum for antibody detection 
was collected immediately prior to inoculation and at weekly intervals. 
Sheep were observed daily after challenge for clinical manifestations 
which were eventually monitored, giving a final score for each animal. 
IMMUNOGENICITY OF BTV-CPOX VACCINE IN GOATS AND 
SHEEP 
Antibodies to capripoxvirus as reveaied by IF A were detected as eariy as 1 
week post-vaccination in some animais and at 2 week post-vaccination in all 
animals (whether vaccinated with irrelevant HPPR-Cpox or BTV-Cpox). 
Three different ELISAs were used to anaiyze anti-NS3, anti-VP7 or anti-
NS 1 antibodies whereas VNT was used for anti-VP2 antibody detection. 
Goats and sheep gave both simiiar resuits. NS3 seroconversion was 
observed as early as 1 week post-irnmunization (Pl) in the BTV-Cpox group 
compared to the control animais which only seroconverted at day 35, 2 
weeks after the virulent challenge. VP7 seroconversion was observed in 
some animais inoculated with the BTV-Cpox recombinant at 3 weeks post 
immunisation ( day 21) and for the whole group at 2 weeks post BTV 
challenge (day 35). The boost of anti-VP7 response at day 35 (Table 3) 
correlated with the anti-NS3 boost observed in the BTV-Cpox group 
animais. ODs of the BTV-Cpox group were significantly different from the 
values of the control group. Due to tecbnjque limüations, anti-NSl antibody 
detection could not be interpreted. Anti-VP2 antibodies were detected by 
VNT in some animais vaccinated with BTV-Cpox group. Ali animais 
seroconverted at day 35. As expected, animais immunized with HPPR-Cpox 
seroconverted to HPPR whereas those irnmunized with BTV-Cpox did not. 
CELL-MEDIATED IMMUNITY IN GOATS 
Antigen specific blastogenesis and lymphocyte proliferation were 
monitored at weekly intervais after the attenuated BTV challenge. A 
BTV specific proliferation was first observed at day 14 for some of the 
BTV-Cpox animais. A significant effect was observed for the whole 
group at day 28 compared to the control group. BTV specific 
blastogenesis correlated with the lympho-proliferation data at day 28. 
Specific lympho-proliferation to whoie Cpox antigens was observed from 
day 28 to day 42 for the BTV-Cpox group and at day 42 only for contrai 
group animais. Simiiar results were obtained for biastogenesis. 
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PARTIAL PROTECTION 
The ability of BTV-Cpox vaccine to protect sheep and goats against disease 
and virus replication was evaluated respectively by scoring clinical signs 
after virulent BTV-2 challenge and by detection of BTV. One sheep out of 
eleven died at day 55 in the BTV-Cpox group whereas three animais out of 
ten died at days 53, 54 and 58 in the control group. The majority of animals 
presented clinical signs but a significant difference was observed between 
the two groups using the Kruskal-Wallis test with a p value <0.001 (***). 
BTV genome was detected in sheep blood at 4 and 7 days post-challenge. 
BTV genome was not detected in BTV-Cpox immunized goats but in control 
group. 
Acknowledgements 
The authors would like to thank Noël Richard, Jean-Michel Guibert, Pascal 
Morel for technical assistance and Merial for providing BTV-2 wild type 
virus. This research was supported in part by the Région Languedoc 
Roussillon, France. 
REFERENCES 
Boone J.D ., Balasuriya U.B., Karaca K, Audonnet J.C., Yao J., He L., Nordgren 
R., Monaco F., Savini G. , Gardner I.A., Maclachlan N.J., 2007. Recombinant 
canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer 
capsid proteins of bluetongue virus induces high level protection in sheep. 
Vaccine, 8, 25 ( 4): 672-678. 
Wade-Evans A.M., Romero C.H., Mellor P.S ., Takamatsu H., Anderson J., 
Thevasagayam J., Fleming M.J., Mertens P.P.C., Black D.N., 1996. Expression 
of the major core structural protein (VP7) of bluetongue virus, by a recombinant 
capripox virus, provides partial protection of sheep against a virulent 
heterotypic bluetongue virus challenge. Virology, 220 (1): 227-231. 
Boyle DB, Coupar AEH., 1988. A dominant selectable marker for the 
construction ofrecombinant poxviruses. Gene, 65: 123-128. 
Falkner FG, Moss B., 1988. Escherichia coti gpt gene provides dominant selection 
for vaccinia virus open reading frame expression vectors. J Virol., 62: 1849-1854. 
Wallace D.B., Viljoen G.J., 2005 . Immnune responses to recombinants of the 
South African vaccine strain of LSDV generated by using thymidine kinase 
gene insertion. Vaccine., 23: 3061-3067. 
Romero CH., Barrett T., Evans S.A., Kitching R.P., Gershon P.D., Bostock C., 
Black D.N., 1993. Single capripoxvirus recombinant vaccine for the protection 
of cattle against rinderpest and lumpy skin disease. Vaccine., 11: 737-742. 
190 Workshop B - New vaccines and consequences of vaccination 
